Targeted Organ Drug Delivery Platform in NHP

Precise drug delivery is critical for the effective treatment of central nervous system (CNS) and organ-specific diseases. Prisys Biotechnologies leverages the genetic and physiological similarities between non-human primates (NHPs) and humans-combined with its team's deep expertise and clinical-grade technologies-to deliver advanced preclinical solutions for targeted organ drug delivery.

Improved Efficacy: By bypassing natural physiological barriers such as the blood-brain barrier (BBB), targeted delivery significantly increases drug concentration at the intended site, enhancing therapeutic outcomes.

Reduced Systemic Toxicity: Limiting drug exposure to non-target tissues minimizes off-target effects and systemic toxicity.

Greater Clinical Relevance: NHP models closely replicate human drug administration conditions, offering predictive, translatable data. These models also provide valuable insights into administration routes, dosage optimization, and treatment frequency-informing more effective clinical protocols.

Core Technologies: Intraprocedural MRI (iMRI) Navigation and Convection-Enhanced Delivery (CED)

Prisys employs an innovative iMRI-guided system that integrates real-time MRI with MRI-compatible surgical tools and software to enable precise neurosurgical planning and accurate catheter navigation to deep brain targets. This is paired with Convection-Enhanced Delivery (CED), a micro-infusion technique that promotes broader and more uniform drug distribution within specific brain regions. Together, these technologies enhance the precision, safety, and effectiveness of intraparenchymal drug delivery.

Prisys' Platform and Applications

Prisys has established Asia's first precision neurosurgical navigation and drug delivery system for non-human primate (NHP) preclinical research, based on intraprocedural MRI (iMRI) technology, at its Shanghai facility. This cutting-edge platform enables MRI-guided drug delivery studies in the brain, supporting high-precision, clinically relev
ant preclinical research.

Prisys' iMRI-guided system has been successfully applied to the delivery of innovative therapies, including gene therapies. In preclinical studies targeting Parkinson's disease, for instance, the platform enabled precise injection of therapeutic agents into the putamen. The system delivers sub-millimetric accuracy, high reproducibility, and real-time monitoring of drug infusion within the brain parenchyma-ensuring precise, effective, and controlled targeted delivery.

Advantages of N2B Delivery:
Intranasal administration offers a non-invasive route for drug delivery to the brain. Key advantages include minimal pain, avoidance of hepatic first-pass metabolism (enhancing bioavailability), ease of administration (which may improve patient compliance), rapid absorption and onset of action, and suitability for patients experiencing nausea or gastrointestinal conditions.

Drug Compatibility and Evaluation Methods:
Prisys' N2B delivery platform supports a wide range of drug formulations. We have established methodologies to visualize and quantify intranasal drug deposition and distribution. In addition, we offer robust capabilities to evaluate systemic biodistribution, providing comprehensive insight into the drug's behavior throughout the body.

Prisys' N2B Delivery Practices: Prisys has established robust technical capabilities for intranasal drug administration, particularly in cynomolgus monkeys. We have developed reproducible in vivo delivery techniques for a variety of drug formulations. For example, computed tomography (CT) imaging is used to accurately evaluate drug deposition in the upper nasal cavity following administration. These practices highlight Prisys' advanced technological platform and extensive research expertise in nose-to-brain delivery.

Prisys' NHP platform integrates a range of clinically established interventional and imaging technologies to support targeted drug delivery to various organs:

Ultrasound-Guided Administration:
Ultrasound imaging is utilized to guide interventional procedures, including intrathecal puncture and catheter placement in NHPs. This technology is a key component of Prisys' comprehensive imaging platform, ensuring precision and safety during drug delivery procedures.

DSA (Digital Subtraction Angiography)-Guided Administration:

DSA, a crucial vascular interventional technique, is used to guide minimally invasive intravascular drug delivery. This includes targeted organ perfusion (e.g., direct infusion into coronary or hepatic arteries) and cerebral administration (e.g., catheter placement in the middle cerebral artery or intraventricular delivery). DSA provides high-resolution imaging, ensuring precise administration and enhancing the accuracy of the procedure.

Biofluid/Tissue Biopsy Techniques:

Prisys is equipped to collect a variety of biofluids (such as blood and cerebrospinal fluid) and tissue samples to support comprehensive analysis in preclinical and clinical studies.

Prisys integrates Asia's first NHP preclinical iMRI system, N2B delivery technology, and advanced clinical imaging tools such as ultrasound and DSA to create a comprehensive platform for targeted organ delivery in NHPs. This approach enhances the precision and efficiency of drug delivery, utilizing the human-like characteristics of NHP models to improve translational relevance and accelerate the drug development process.

Hot Tags: targeted organ drug delivery platform in nhp, research, study, monkey, gene therapy, translational toxicology, testing on primates, Translational, NHP translation, NHP drug target, testing monkeys